B-Lymphoblastic Leukemia / Lymphoma · line 2 · Blinatumomab BiTE for MRD+ post-induction OR R/R B-ALL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-BLINATUMOMAB-B-ALL |
| ID | IND-B-ALL-BLINATUMOMAB-MRD-OR-RR |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-B-ALL |
| Sources | SRC-BLAST-GOKBUGET-2018 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track for MRD+ post-induction OR R/R B-ALL. Bridge-to-HCT intent dominant. Ukraine access barrier. Time-critical (acute leukemia).
Used By
Algorithms
ALGO-B-ALL-2L- ALGO-B-ALL-2L